Back to search results

Nicotinamide Riboside Supplementation in Chronic Kidney Disease

This study is looking at whether a dietary supplement called Nicotinamide Riboside (a form of vitamin B3) can be used safely and effectively by adults with moderate chronic kidney disease (CKD). You might be able to join if you are between 30 and 99 years old, have moderate CKD (eGFR 30-59 mL/min/1.73 m2), and your urine albumin-to-creatinine ratio (uACR) is less than 300 mg/g. The main goal is to see if it's practical for people with CKD to take Nicotinamide Riboside daily and complete study visits. Researchers will also explore if Nicotinamide Riboside affects markers of cell health and physical function. You will either take Nicotinamide Riboside first and then a matched placebo (an inactive capsule that looks the same), or vice versa.

Study design
This is a randomized, double-blind, placebo-controlled crossover study with 30 participants. This means participants are randomly assigned to receive either Nicotinamide Riboside or a placebo first, and neither you nor the study staff will know which you are taking at any given time.
What's involved
You will take either Nicotinamide Riboside or a placebo orally for 12 weeks during each treatment period. Study visits will occur at Baseline, Week 12, and Week 26.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for at least 26 weeks, with measurements taken at Baseline, Week 12, and Week 26.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07693543

Nicotinamide Riboside Supplementation in Chronic Kidney Disease

Not Yet Recruiting
PHASE2Ages 30+InterventionalTreatment
University of California, San Diego
~30 participants
Updated 2026-07-15 on ClinicalTrials.gov
What's tested:Nicotinamide Riboside (NR)Matched Placebo (Capsules)

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in plasma cell-free mitochondrial DNA
Measured over Baseline, Week 12, and Week 26
+1 more outcome measured

Conditions

Chronic Kidney Disease

Explore related trials

Chronic Kidney Disease

NCT07693543

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Altman Clinical and Translation Research Institute

    San Diego, Californiastudy coordinator listed

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Armin Ahmadi, PhD · PRINCIPAL_INVESTIGATOR · University of California, San Diego

Who to contact

Armin Ahmadi, PhD
[email protected]
619-543-6248
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Moderate chronic kidney disease not treated with dialysis, defined as eGFR 30-59 mL/min/1.73 m2 using the CKD-EPI equation.
Urine albumin-to-creatinine ratio (uACR) \<300 mg/g.
Able to provide informed consent.
Able to walk unassisted from room to room, with usual assistive device allowed if approved by study safety assessment.
Willing and able to comply with study procedures, visits, and study product administration.

Exclusion

Pregnancy.
Expectation to start dialysis within 6 months.
Unable to walk unassisted from room to room.
Institutionalization or inability to consent.
End-stage liver disease with cirrhosis.
HIV.
Oxygen-dependent COPD.
Baseline systolic blood pressure \>170 mmHg or diastolic blood pressure \>100 mmHg.
Current participation in another interventional trial.
Use of immunosuppressive medications, including steroids or calcineurin inhibitors.
Malignancy requiring active treatment or currently under surveillance at the discretion of the investigator.
Hospitalization for myocardial infarction, unstable angina, cerebrovascular accident, or unstable cardiac chest pain within the prior 3 months.

What this trial measures

  • Change in plasma cell-free mitochondrial DNABaseline, Week 12, and Week 26

    Change in plasma cell-free mitochondrial DNA concentration, measured as mitochondrial DNA copies per mL of plasma using droplet digital PCR.

  • Change in urine cell-free mitochondrial DNABaseline, Week 12, and Week 26

    Change in urine cell-free mitochondrial DNA concentration, measured using droplet digital PCR and reported as mitochondrial DNA copies normalized to urine osmolarity.